4.6 Article

Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition

Journal

ONCOIMMUNOLOGY
Volume 6, Issue 2, Pages -

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2016.1274476

Keywords

CD8(+) T cells; colon cancer; immune evasion; lung cancer; MHC class I; tapasin

Funding

  1. Japan Society for the Promotion of Science
  2. Suhara Kinen Zaidan
  3. Northern Advancement Center for Science & Technology of Hokkaido Japan
  4. Japan Agency for Medical Research and development
  5. Ministry of Education, Culture, Sports, Science and Technology of Japan
  6. Health and Labor Sciences Research Grants

Ask authors/readers for more resources

Cytotoxic T-lymphocytes (CTLs) lyse target cells after recognizing the complexes of peptides and MHC class I molecules (pMHC I) on cell surfaces. Tapasin is an essential component of the peptide-loading complex (PLC) and its absence influences the surface repertoire of MHC class I peptides. In the present study, we assessed tapasin expression in 85 primary tumor lesions of non-small cell lung cancer (NSCLC) patients, demonstrating that tapasin expression positively correlated with patient survival. CD8(+) T-cell infiltration of tumor lesions was synergistically observed with tapasin expression and correlated positively with survival. To establish a direct link between loss of tapasin and CTL recognition in human cancer models, we targeted the tapasin gene by CRISPR/Cas9 system and generated tapasin-deficient variants of human lung as well as colon cancer cells. We induced the CTLs recognizing endogenous tumor-associated antigens (TAA), survivin or cep55, and they responded to each tapasin-proficient wild type. In contrast, both CTL lines ignored the tapasin-deficient variants despite their antigen expression. Moreover, the adoptive transfer of the cep55-specific CTL line failed to prevent tumor growth in mice bearing the tapasindeficient variant. Loss of tapasin most likely limited antigen processing of TAAs and led to escape from TAA-specific CTL recognition. Tapasin expression is thus a key for CTL surveillance against human cancers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy

Haruka Miyata, Yoshihiko Hirohashi, Shuhei Yamada, Junko Yanagawa, Aiko Murai, Shinichi Hashimoto, Serina Tokita, Kanta Hori, Takashige Abe, Terufumi Kubo, Tomohide Tsukahara, Takayuki Kanaseki, Nobuo Shinohara, Toshihiko Torigoe

Summary: Recent studies have shown that treatment-resistant cancer stem-like cells can be targeted by cytotoxic T lymphocytes, with a specific antigenic peptide (LMYDAVHVV) derived from GRIK2 being identified as a potential novel target for bladder CSC/CIC immunotherapy.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Article Oncology

Tumor-infiltrating CD8(+) T cells recognize a heterogeneously expressed functional neoantigen in clear cell renal cell carcinoma

Masahiro Matsuki, Yoshihiko Hirohashi, Munehide Nakatsugawa, Aiko Murai, Terufumi Kubo, Shinichi Hashimoto, Serina Tokita, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Sachiyo Nishida, Toshiaki Tanaka, Hiroshi Kitamura, Naoya Masumori, Toshihiko Torigoe

Summary: ICIs are used in cancer immunotherapy to block certain pathways, but low response rates and tumor heterogeneity can lead to resistance. This study found that the specificity of TILs in RCC may be related to gene mutations and reactivity, suggesting heterogenous tumors may have diverse gene mutations and responses to TILs.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Article Biochemistry & Molecular Biology

High aldehyde dehydrogenase 1 activity is related to radiation resistance due to activation of AKT signaling after insulin stimulation in prostate cancer

Takahito Wakamiya, Yoshihiko Hirohashi, Aiko Murai, Junko Yanagawa, Yuka Mizue, Terufumi Kubo, Shinichi Hashimoto, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Sachiyo Nishida, Yasuo Kohjimoto, Isao Hara, Toshihiko Torigoe

Summary: The ALDH1-high prostate cancer stem-like cells (CSCs) exhibit heterogeneity in tumorigenicity and resistance to radiation and chemotherapy, along with lower levels of phosphorylated AKT. Insulin can activate AKT signaling in these cells, leading to resistance to radiation and chemotherapy. These findings suggest a potential mechanism for treatment resistance in prostate cancer.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2022)

Review Radiology, Nuclear Medicine & Medical Imaging

Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy

Masanori Someya, Yuki Fukushima, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoh Kozuka, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Koh-Ichi Sakata

Summary: This review discusses the application of radiotherapy for human papillomavirus (HPV)-related cancer and the mechanism of tumor immunity. It also explores how chemoradiotherapy can improve the efficacy of tumor immunity. Additionally, it highlights the usefulness of tumor immunity-related proteins as predictive markers of radiotherapy response, and provides an overview of ongoing clinical trials of combinations of immune checkpoint inhibitors and radiotherapy.

JAPANESE JOURNAL OF RADIOLOGY (2022)

Article Oncology

A screening assistance system for cervical cytology of squamous cell atypia based on a two-step combined CNN algorithm with label smoothing

Yuta Nambu, Tasuku Mariya, Shota Shinkai, Mina Umemoto, Hiroko Asanuma, Ikuma Sato, Yoshihiko Hirohashi, Toshihiko Torigoe, Yuichi Fujino, Tsuyoshi Saito

Summary: This study developed a fast and accurate system for detecting and classifying atypical cell clusters using two different deep learning algorithms. The combination of YOLOv4 and ResNeSt algorithms allowed the system to effectively handle overlapping and crowded cell images, achieving high accuracy in cell detection and classification.

CANCER MEDICINE (2022)

Article Oncology

Identification of Neoantigens in Two Murine Gastric Cancer Cell Lines Leading to the Neoantigen-Based Immunotherapy

Koji Nagaoka, Changbo Sun, Yukari Kobayashi, Takayuki Kanaseki, Serina Tokita, Toshihiro Komatsu, Kazuhiro Maejima, Junichiro Futami, Sachiyo Nomura, Keiko Udaka, Hidewaki Nakagawa, Toshihiko Torigoe, Kazuhiro Kakimi

Summary: Despite the success of immune checkpoint inhibitors (ICI) in treating solid cancers, most gastric cancer patients are resistant to ICI monotherapies. This study characterized two murine gastric cancer cell lines, YTN2 and YTN16, and identified new antigens. The findings suggest that combination immunotherapy can effectively inhibit gastric cancer growth, providing a basis for the development of novel combination immunotherapies.

CANCERS (2022)

Article Gastroenterology & Hepatology

HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability

Masahito Kawazu, Toshihide Ueno, Koichi Saeki, Nicolas Sax, Yosuke Togashi, Takayuki Kanaseki, Keigo Chida, Fumishi Kishigami, Kazuhito Sato, Shinya Kojima, Masafumi Otsuka, Akihito Kawazoe, Hitomi Nishinakamura, Maeda Yuka, Yoko Yamamoto, Kazuo Yamashita, Satoshi Inoue, Tokiyoshi Tanegashima, Daisuke Matsubara, Kenta Tane, Yosuke Tanaka, Hisae Iinuma, Yojiro Hashiguchi, Shoichi Hazama, Seik-Soon Khor, Katsushi Tokunaga, Masahiro Tsuboi, Toshiro Niki, Masatoshi Eto, Kohei Shitara, Toshihiko Torigoe, Soichiro Ishihara, Hiroyuki Aburatani, Hiroshi Haeno, Hiroyoshi Nishikawa, Hiroyuki Mano

Summary: This study analyzed mutations in HLA-ABC genes in colorectal cancers and found a subtype of tumors with reduced lymphocyte infiltration due to decreased expression of HLA-ABC genes. Patients with these tumors had shorter survival time, despite having a higher tumor mutation burden, suggesting a counterbalance between immunogenic effects and weakened immunoreactivity. Various genetic and epigenetic alterations led to reduced expression of HLA-ABC genes.

GASTROENTEROLOGY (2022)

Article Oncology

Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma

Takashi Sasaya, Terufumi Kubo, Kenji Murata, Yuka Mizue, Kenta Sasaki, Junko Yanagawa, Makoto Imagawa, Hirotaka Kato, Tomohide Tsukahara, Takayuki Kanaseki, Yasuaki Tamura, Akihiro Miyazaki, Yoshihiko Hirohashi, Toshihiko Torigoe

Summary: This study investigates the effects of cisplatin on the immunotherapy response of oral squamous cell carcinoma (OSCC) and finds that cisplatin increases the surface levels of PD-L1 on OSCC cells but does not alter gene and total protein expression levels. Moreover, cisplatin-induced PD-L1 attenuates the cytotoxic T lymphocyte reaction to OSCC.

CANCER MEDICINE (2023)

Article Biochemistry & Molecular Biology

G-Protein-Coupled Receptors Mediate Modulations of Cell Viability and Drug Sensitivity by Aberrantly Expressed Recoverin 3 within A549 Cells

Hanae Ichioka, Yoshihiko Hirohashi, Tatsuya Sato, Masato Furuhashi, Megumi Watanabe, Yosuke Ida, Fumihito Hikage, Toshihiko Torigoe, Hiroshi Ohguro

Summary: To investigate the molecular mechanisms responsible for aberrant expression of recoverin (Rec) in cancer cells, Rec-negative lung adenocarcinoma cells (A549) were transfected with a human recoverin cDNA plasmid (A549 Rec) or an empty plasmid (A549 MOCK). The A549 Rec cells showed increased sensitivity to anti-tumor agents, altered cellular metabolism, and formation of larger and stiffer 3D spheroids compared to A549 MOCK. RNA sequencing analysis suggested that aberrantly expressed Rec may be associated with G-protein-coupled receptor (GPCR)-mediated signaling and the cAMP response element binding protein (CREB) signaling pathway.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer

Bernhard Mlecnik, Alessandro Lugli, Gabriela Bindea, Florence Marliot, Carlo Bifulco, Jiun-Kae Jack Lee, Inti Zlobec, Tilman T. Rau, Martin D. Berger, Iris D. Nagtegaal, Elisa Vink-Borger, Arndt Hartmann, Carol Geppert, Julie Kolwelter, Susanne Merkel, Robert Grutzmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Leonard, Christophe Remue, Julia Wang, Prashant Bavi, Michael H. A. Roehrl, Pamela S. Ohashi, Linh T. Nguyen, SeongJun Han, Heather L. MacGregor, Sara Hafezi-Bakhtiari, Bradly G. Wouters, Giuseppe Masucci, Emilia K. Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Tessa Fredriksen, Benedicte Buttard, Lucie Lafontaine, Pauline Maby, Amine Majdi, Assia Hijazi, Carine El Sissy, Amos Kirilovsky, Anne Berger, Christine Lagorce, Christopher Paustian, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn van de Water, Shannon Van Lent-van Vliet, Nikki Knijn, Ana-Maria Musing, Dragos-Viorel Scripcariu, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Toshihiko Torigoe, Noriyuki Sato, Tomohisa Furuhata, Ichiro Takemasa, Prabhu Patel, Hemangini H. Vora, Birva Shah, Jayendrakumar B. Patel, Kruti N. Rajvik, Shashank J. Pandya, Shilin N. Shukla, Yili Wang, Guanjun Zhang, Yutaka Kawakami, Francesco M. Marincola, Paolo A. Ascierto, Bernard A. Fox, Franck Pages, Jerome Galon

Summary: This study found that the immune system status is a better predictor of prognosis in early-stage colon cancer patients than tumor cell-related parameters. The consensus Immunoscore accurately identifies early-stage colon cancer patients with different clinical outcomes, regardless of treatment bias.

CANCERS (2023)

Article Oncology

Exploring olfactory receptor family 7 subfamily C member 1 as a novel oral cancer stem cell target for immunotherapy

Sho Miyamoto, Yoshihiko Hirohashi, Rena Morita, Akihiro Miyazaki, Kazuhiro Ogi, Takayuki Kanaseki, Kentaro Ide, Jumpei Shirakawa, Tomohide Tsukahara, Aiko Murai, Takashi Sasaya, Kazushige Koike, Shinichiro Kina, Toshihiro Kawano, Takahiro Goto, Edward Hosea Ntege, Yusuke Shimizu, Toshihiko Torigoe

Summary: Despite advances in cancer therapies, the mortality rate of oral cancer has not improved in the past three decades. Oral cancers contain a subpopulation of cancer stem cells (CSCs) that contribute to cancer infiltration, recurrence, metastasis, and drug resistance. Cytotoxic CD8+ T lymphocytes (CTLs) play a crucial role in targeting CSCs and regulating cancer progression. This study investigates the potential of olfactory receptor family 7 subfamily C member 1 (OR7C1) as a target for CSC-targeted immunotherapy in oral cancer and finds that OR7C1 is expressed only in oral CSCs and is effectively recognized by CTLs.

CANCER SCIENCE (2023)

Article Oncology

ACLP Activates Cancer-Associated Fibroblasts and Inhibits CD8+T-Cell Infiltration in Oral Squamous Cell Carcinoma

Shohei Sekiguchi, Akira Yorozu, Fumika Okazaki, Takeshi Niinuma, Akira Takasawa, Eiichiro Yamamoto, Hiroshi Kitajima, Toshiyuki Kubo, Yui Hatanaka, Koyo Nishiyama, Kazuhiro Ogi, Hironari Dehari, Atsushi Kondo, Makoto Kurose, Kazufumi Obata, Akito Kakiuchi, Masahiro Kai, Yoshihiko Hirohashi, Toshihiko Torigoe, Takashi Kojima, Makoto Osanai, Kenichi Takano, Akihiro Miyazaki, Hiromu Suzuki

Summary: This study demonstrates that aortic carboxypeptidase-like protein (ACLP) is highly expressed in cancer-associated fibroblasts (CAFs) in oral squamous cell carcinoma (OSCC) and is activated by cancer cell-induced TGF-β1 signaling pathway. ACLP derived from CAFs enhances migration and infiltration of cancer cells. Furthermore, ACLP is co-expressed with collagen and negatively correlates with tumor infiltration of CD8+ T lymphocytes, suggesting a potential therapeutic target for stromal-targeted therapy and cancer immunotherapy.

CANCERS (2023)

Article Oncology

Multi-Institutional Evaluation of Pathologists' Assessment Compared to Immunoscore

Joseph Willis, Robert A. Anders, Toshihiko Torigoe, Yoshihiko Hirohashi, Carlo Bifulco, Inti Zlobec, Bernhard Mlecnik, Sandra Demaria, Won-Tak Choi, Pavel Dundr, Fabiana Tatangelo, Annabella Di Mauro, Pamela Baldin, Gabriela Bindea, Florence Marliot, Nacilla Haicheur, Tessa Fredriksen, Amos Kirilovsky, Benedicte Buttard, Angela Vasaturo, Lucie Lafontaine, Pauline Maby, Carine El Sissy, Assia Hijazi, Amine Majdi, Christine Lagorce, Anne Berger, Marc van den Eynde, Franck Pages, Alessandro Lugli, Jerome Galon

Summary: This study compares the performance of a standardized Immunoscore (IS) digital pathology assay to visual examination by expert pathologists. The results show that the IS assay outperforms the pathologists' evaluation in the clinical setting, demonstrating the potential of IS as an immune pathology tool. These findings can contribute to better diagnosis and prognosis of cancer patients and highlight the importance of digital pathology in cancer management.

CANCERS (2023)

Article Medicine, Research & Experimental

Proteogenomic identification of an immunogenic antigen derived from human endogenous retrovirus in renal cell carcinoma

Shin Kobayashi, Serina Tokita, Keigo Moniwa, Katsuyuki Kitahara, Hiromichi Iuchi, Kazuhiko Matsuo, Hidehiro Kakizaki, Takayuki Kanaseki, Toshihiko Torigoe

Summary: CD8+ T cells can recognize and eliminate tumor cells by targeting tumor antigens displayed by HLA class I molecules. In this study, the presence of immunogenic hERV antigens in renal cell carcinoma tissues was identified, and their potential clinical applications in patients with RCC were suggested.

JCI INSIGHT (2023)

Review Immunology

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy

Terufumi Kubo, Yoshihiko Hirohashi, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Rena Morita, Toshihiko Torigoe

Summary: Despite the success of cancer immunotherapy using immune checkpoint inhibitors, the nonspecific release of immunosuppressive mechanisms can lead to immune-related adverse events (irAEs) that significantly impact patients' quality of life. Proper management of irAEs is crucial for the advancement of reliable cancer immunotherapies. IrAEs resemble autoimmune diseases but often have distinct features, and while the detailed pathogenesis remains unclear, numerous studies are providing insights into this phenomenon.

IMMUNOLOGICAL MEDICINE (2022)

No Data Available